Miguel L Prieto1, Louis A Schenck2, Jennifer L Kruse3, James P Klaas4, Alanna M Chamberlain5, William V Bobo6, Frank Bellivier7, Marion Leboyer8, Véronique L Roger9, Robert D Brown4, Walter A Rocca10, Mark A Frye11. 1. Department of Psychiatry and Psychology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA; Universidad de los Andes, Facultad de Medicina, Departamento de Psiquiatría, Santiago, Chile. 2. Division of Biomedical Statistics, Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN 55905, USA. 3. Department of Psychiatry and Psychology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA; Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA, USA. 4. Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA. 5. Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN 55905, USA. 6. Department of Psychiatry and Psychology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA. 7. AP-HP, GH Saint-Louis - Lariboisière - F. Widal, Département de Psychiatrie et de Médecine Addictologique, 75475 Paris Cedex 10, France; Université Paris Diderot, Sorbonne Paris Cité, UMR-S 1144, Paris F-75013, France; Fondation FondaMental, Créteil, France. 8. Fondation FondaMental, Créteil, France; Université Paris Est, Faculté de Médecine, Créteil, France; INSERM, U955, Psychiatrie Génétique, Créteil, France; Hôpital H. Mondor-A. Chenevier, Département de Psychiatrie, Créteil, France. 9. Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN 55905, USA; Division of Cardiovascular Diseases, Department of Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA. 10. Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA; Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN 55905, USA. 11. Department of Psychiatry and Psychology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA. Electronic address: mfrye@mayo.edu.
Abstract
OBJECTIVES: To estimate the risk of fatal and non-fatal myocardial infarction (MI) and stroke in patients with bipolar I disorder compared to people without bipolar I disorder. METHOD: Utilizing a records-linkage system spanning 30 years (1966-1996), a population-based cohort of 334 subjects with bipolar I disorder and 334 age and sex-matched referents from Olmsted County, Minnesota, U.S. was identified. Longitudinal follow-up continued until incident MI or stroke (confirmed by board-certified cardiologist/neurologist), death, or study end date (December 31, 2013). Cox proportional hazards models assessed the hazard ratio (HR) for MI or stroke, adjusting for potential confounders. RESULTS: There was an increased risk of fatal or non-fatal MI or stroke (as a composite outcome) in patients with bipolar I disorder [HR 1.54, 95% confidence interval (CI) 1.02, 2.33; p=0.04]. However, after adjusting for baseline cardiovascular risk factors (alcoholism, hypertension, diabetes, and smoking), the risk was no longer significantly increased (HR 1.19, 95% CI 0.76, 1.86; p=0.46). LIMITATIONS: Small sample size for the study design. Findings were not retained after adjustment for cardiovascular disease risk factors. Psychotropic medication use during the follow-up was not ascertained and was not included in the analyses. CONCLUSION: This study in a geographically defined region in the U.S. demonstrated a significant increased risk of MI or stroke in bipolar I disorder, which was no longer significant after adjustment for cardiovascular risk factors.
OBJECTIVES: To estimate the risk of fatal and non-fatal myocardial infarction (MI) and stroke in patients with bipolar I disorder compared to people without bipolar I disorder. METHOD: Utilizing a records-linkage system spanning 30 years (1966-1996), a population-based cohort of 334 subjects with bipolar I disorder and 334 age and sex-matched referents from Olmsted County, Minnesota, U.S. was identified. Longitudinal follow-up continued until incident MI or stroke (confirmed by board-certified cardiologist/neurologist), death, or study end date (December 31, 2013). Cox proportional hazards models assessed the hazard ratio (HR) for MI or stroke, adjusting for potential confounders. RESULTS: There was an increased risk of fatal or non-fatal MI or stroke (as a composite outcome) in patients with bipolar I disorder [HR 1.54, 95% confidence interval (CI) 1.02, 2.33; p=0.04]. However, after adjusting for baseline cardiovascular risk factors (alcoholism, hypertension, diabetes, and smoking), the risk was no longer significantly increased (HR 1.19, 95% CI 0.76, 1.86; p=0.46). LIMITATIONS: Small sample size for the study design. Findings were not retained after adjustment for cardiovascular disease risk factors. Psychotropic medication use during the follow-up was not ascertained and was not included in the analyses. CONCLUSION: This study in a geographically defined region in the U.S. demonstrated a significant increased risk of MI or stroke in bipolar I disorder, which was no longer significant after adjustment for cardiovascular risk factors.
Authors: M L Prieto; A B Cuéllar-Barboza; W V Bobo; V L Roger; F Bellivier; M Leboyer; C P West; M A Frye Journal: Acta Psychiatr Scand Date: 2014-05-22 Impact factor: 6.392
Authors: Jennifer L St Sauver; Brandon R Grossardt; Barbara P Yawn; L Joseph Melton; Joshua J Pankratz; Scott M Brue; Walter A Rocca Journal: Int J Epidemiol Date: 2012-11-18 Impact factor: 7.196
Authors: Véronique L Roger; Susan A Weston; Yariv Gerber; Jill M Killian; Shannon M Dunlay; Allan S Jaffe; Malcolm R Bell; Jan Kors; Barbara P Yawn; Steven J Jacobsen Journal: Circulation Date: 2010-02-08 Impact factor: 29.690
Authors: Jennifer L St Sauver; Brandon R Grossardt; Barbara P Yawn; L Joseph Melton; Walter A Rocca Journal: Am J Epidemiol Date: 2011-03-23 Impact factor: 4.897
Authors: Mauricio Tohen; Carlos A Zarate; John Hennen; Hari-Mandir Kaur Khalsa; Stephen M Strakowski; Priscilla Gebre-Medhin; Paola Salvatore; Ross J Baldessarini Journal: Am J Psychiatry Date: 2003-12 Impact factor: 18.112
Authors: Amy M Kilbourne; David E Goodrich; Zongshan Lai; Edward P Post; Karen Schumacher; Kristina M Nord; Margretta Bramlet; Stephen Chermack; David Bialy; Mark S Bauer Journal: J Clin Psychiatry Date: 2013-07 Impact factor: 4.384
Authors: Christoph U Correll; Marco Solmi; Nicola Veronese; Beatrice Bortolato; Stella Rosson; Paolo Santonastaso; Nita Thapa-Chhetri; Michele Fornaro; Davide Gallicchio; Enrico Collantoni; Giorgio Pigato; Angela Favaro; Francesco Monaco; Cristiano Kohler; Davy Vancampfort; Philip B Ward; Fiona Gaughran; André F Carvalho; Brendon Stubbs Journal: World Psychiatry Date: 2017-06 Impact factor: 49.548
Authors: Moein Foroughi; Jose R Medina Inojosa; Francisco Lopez-Jimenez; Farzane Saeidifard; Laura Suarez; Gorazd B Stokin; Miguel L Prieto; Walter A Rocca; Mark A Frye; Robert J Morgan Journal: Psychosom Med Date: 2022-01-01 Impact factor: 4.312
Authors: Benjamin I Goldstein; Bernhard T Baune; David J Bond; Pao-Huan Chen; Lisa Eyler; Andrea Fagiolini; Fabiano Gomes; Tomas Hajek; Jessica Hatch; Susan L McElroy; Roger S McIntyre; Miguel Prieto; Louisa G Sylvia; Shang-Ying Tsai; Andrew Kcomt; Jess G Fiedorowicz Journal: Bipolar Disord Date: 2020-06-08 Impact factor: 6.744
Authors: Amanda M Lambert; Helen M Parretti; Emma Pearce; Malcolm J Price; Mark Riley; Ronan Ryan; Natalie Tyldesley-Marshall; Tuba Saygın Avşar; Gemma Matthewman; Alexandra Lee; Khaled Ahmed; Maria Lisa Odland; Christoph U Correll; Marco Solmi; Tom Marshall Journal: PLoS Med Date: 2022-04-19 Impact factor: 11.613